I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

J. Christopher Naftzger net worth and biography

J. Christopher Naftzger Biography and Net Worth

General Counsel of Nabriva Therapeutics

Christopher Naftzger re-joined Nabriva Therapeutics in September 2021. He has more than 25 years of legal experience, including over a decade of experience serving in senior in-house counsel positions with life science companies. He most recently served as General Counsel and Corporate Secretary of Krystal Biotech (NASDAQ: KRYS), an emerging-stage, gene therapy company. Before joining Krystal, he was Vice President, Deputy General Counsel and Assistant Secretary of Nabriva Therapeutics. Prior to Nabriva, Mr. Naftzger served as Vice President, General Counsel, Chief Compliance Officer, and Secretary of Unilife Medical Solutions, a developer and manufacturer of innovative drug delivery systems. Mr. Naftzger also held senior in-house counsel positions with Chesapeake Corporation and Koch Industries, and was a corporate partner with Blank Rome LLP in Washington, DC. Mr. Naftzger obtained his undergraduate degree from Hampden-Sydney College and his law degree from the Willamette University College of Law.

How old is J. Christopher Naftzger?: Mr. Naftzger is currently 56 years old. There are 2 older executives and no younger executives at Nabriva Therapeutics. The oldest executive at Nabriva Therapeutics is Dr. Colin Broom M.D., Director, who is 67 years old. Learn More on J. Christopher Naftzger's age.
How do I contact J. Christopher Naftzger?: The corporate mailing address for Mr. Naftzger and other Nabriva Therapeutics executives is 25-28 NORTH WALL QUAY IFSC, DUBLIN L2, 19406. Nabriva Therapeutics can also be reached via phone at (531) 649-2000 and via email at [email protected]. Learn More on J. Christopher Naftzger's contact information.
Has J. Christopher Naftzger been buying or selling shares of Nabriva Therapeutics?: J. Christopher Naftzger has not been actively trading shares of Nabriva Therapeutics during the past quarter. Learn More on J. Christopher Naftzger's trading history.
Who are Nabriva Therapeutics' active insiders?: Nabriva Therapeutics' insider roster includes J. Christopher Naftzger (General Counsel), Theodore Schroeder (CEO), and Stephen Webster (Director). Learn More on Nabriva Therapeutics' active insiders.

J. Christopher Naftzger Insider Trading History at Nabriva Therapeutics

J. Christopher Naftzger Buying and Selling Activity at Nabriva Therapeutics

Nabriva Therapeutics Company Overview

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.

Today's Range

Now: N/A

50 Day Range

MA: $0.03

$0.00

$1.42

2 Week Range

Now: N/A

Volume

40 shs

Average Volume

29,344 shs

Market Capitalization

$45.46 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.53

This Crypto Is Set to Explode in December

From Crypto 101 Media | Ad

It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…

YES, I WANT THE #1 CRYPTO NOW